Press
Releases
Press Releases
AVROBIO to Present at the Cowen and Company 40th Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 24, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay , president and CEO of AVROBIO , will present at the Cowen and Company 40 th
Feb 24, 2020
AVROBIO Announces Closing of Underwritten Public Offering
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 18, 2020-- AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 4,350,000 shares of its common stock.
Feb 18, 2020
AVROBIO Announces Pricing of Underwritten Public Offering of $100 Million of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 4,350,000 shares of its common stock at a public offering price of $23.00 per share.
Feb 12, 2020
AVROBIO Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering.
Feb 12, 2020
AVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and plato™ Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program
Early data trends from first patient dosed in the AVR-RD-04 investigational gene therapy program for cystinosis show improvements across multiple measures Data from the Phase 1 and Phase 2 trials of AVR-RD-01 support potential long-term engraftment and durable, endogenous production of functional
Feb 10, 2020
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 6, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an
Feb 06, 2020
AVROBIO Announces Clinical Data Presentation and Multiple Events at WORLDSymposium™ 2020
Analyst and investor event to be webcast on Monday, Feb. 10, 2020 , at 7:00 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 4, 2020-- AVROBIO , Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that
Feb 04, 2020
AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program
FDA clears IND application for AVR-RD-02 First patient consented in GAU-201, a global Phase 1/2 trial of AVR-RD-02 in Gaucher disease type 1 All global clinical sites will be supported by proprietary plato ™ platform CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan.
Jan 14, 2020
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 9, 2020-- AVROBIO (NASDAQ: AVRO) (the “Company”), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the Company has granted a non-statutory stock option to a new employee as